Skip to main content

Advertisement

SpringerLink
Log in

Endothelial dysfunction and atherosclerosis: Endothelin receptor antagonists as novel therapeutics

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Atherosclerosis, a chronic systemic disease of the vasculature with an inflammatory component, is the primary cause of cardiovascular morbidity and mortality in industrialized countries [1]. It is associated with the impairment of endothelium-dependent relaxation in the coronary, systemic circulation due to decreased bioavailability of nitric oxide, and increased release oxygen-derived free radicals, thus promoting vasoconstriction, leukocyte adhesion, thrombosis, inflammation, and cell proliferation [2]. Expression of endothelin (ET)-1, a 21-amino acid peptide and major isoform of the endothelin peptide family, is produced by endothelial, vascular smooth muscle cells, and macrophages and acts through Gi-protein-coupled ETA and ETB receptors. Endothelin-1 increases in hypercholesterolemia and atherosclerosis in humans and experimental animals. This paper reviews current experimental and clinical evidence for the involvement of ET-1 in atherogenesis. Furthermore, the effects of ET receptor blockade on experimental hypercholesterolemia and atherosclerosis will be discussed. As chronic endothelin blockade inhibits fatty streak formation and improves vascular function in experimental hypercholesterolemia, hypertension, and heart failure, and as it restores nitric oxide (NO)-mediated endothelial function and reduces atheroma formation in animals with atherosclerosis, endothelin receptor blockade may therefore offer a novel approach for the treatment of atherosclerosis and its vascular complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Recently published papers of particular interest have been

  1. Ross R: The pathogenesis of atherosclerosis. A perspective for the 1990s. Nature 1993, 362:801–809.

    Article  CAS  PubMed  Google Scholar 

  2. Beckmann JS, Koppenol WH: Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996, 271:C1424-C1437.

    Google Scholar 

  3. Napoli C, D’Armiento FP, Mancini FP, et al.: Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997, 100:2680–2690.

    CAS  PubMed  Google Scholar 

  4. Napoli C, Glass CK, Witztum JL, et al.: Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study [see comments]. Lancet 1999, 354:1234–1241.

    Article  CAS  PubMed  Google Scholar 

  5. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 299:373–376.

    Article  Google Scholar 

  6. Ignarro LJ, Buga GM, Wood KS, et al.: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84:9265–9269.

    Article  CAS  PubMed  Google Scholar 

  7. Freiman PC, Mitchell GG, Heistad DD, et al.: Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986, 58:783–789.

    CAS  PubMed  Google Scholar 

  8. Bossaller C, Habib GB, Yamamoto H, et al.: Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5’-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987, 79:170–174.

    CAS  PubMed  Google Scholar 

  9. Harrison DG, Armstrong ML, Freiman PC, Heistad DD: Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987, 80:1808–1811.

    CAS  PubMed  Google Scholar 

  10. Harrison DG, Freiman PC, Armstrong ML, et al.: Alterations of vascular reactivity in atherosclerosis. Circ Res 1987, 61:II74-II80.

    CAS  PubMed  Google Scholar 

  11. Lüscher TF, Boulanger CM, Yang Z, et al.: Interactions between endothelium-derived relaxing and contracting factors in health and disease. Circulation 1993, 87:V36-V44.

    Google Scholar 

  12. De Mey JG, Vanhoutte PM: Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 1982, 51:439–447.

    PubMed  Google Scholar 

  13. Hickey KA, Rubanyi GM, Paul RJ, Highsmith RF: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985, 248:C550-C556.

    CAS  PubMed  Google Scholar 

  14. Gillespie MN, Owasoyo JO, McMurtry IF, O’Brien RF: Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J Pharmacol Exp Ther 1986, 236:339–343.

    CAS  PubMed  Google Scholar 

  15. O’Brien RF, Robbins RJ, McMurtry IF: Endothelial cells in culture produce a vasoconstrictor substance. J Cell Physiol 1987, 132:263–270.

    Article  CAS  PubMed  Google Scholar 

  16. Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411–415.

    Article  CAS  PubMed  Google Scholar 

  17. Yanagisawa M, Inoue A, Ishikawa T, et al.: Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A 1988, 85:6964–6967.

    Article  CAS  PubMed  Google Scholar 

  18. Inoue A, Yanagisawa M, Kimura S, et al.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989, 86:2863–2867.

    Article  CAS  PubMed  Google Scholar 

  19. Miyauchi T, Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999, 61:391–415. Excellent up-to-date review of the pathophysiologic role of the endothelin system.

    Article  CAS  PubMed  Google Scholar 

  20. Saida K, Mitsui Y, Ishida N: A novel peptide, vasoactive intestianl contractor, of a new (endothelin) peptide family: Molecular cloning, expression, and biological activity. J Biol Chem 1989, 264:14613–14616.

    CAS  PubMed  Google Scholar 

  21. Bloch KD, Hong CC, Eddy RL, et al.: cDNA cloning and chromosomal assignment of the endothelin-2 gene: vasoctive intestinal contractor peptide is rat endothelin-2. Genomics 1991, 10:236–242.

    Article  CAS  PubMed  Google Scholar 

  22. Kishi F, Minami K, Okishima N, et al.: Novel 31-amino acid-length endothelins cause constriction of vascular smooth muscle. Biochem Biophys Res Commun 1998, 248:387–390.

    Article  CAS  PubMed  Google Scholar 

  23. Fernandez-Patron C, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999, 85:906–911. This important study provides evidence for a novel ET-1 isoform, ET-1 (1-32), which is produced by MMP-2 primarily in vascular smooth muscle and has very potent vasoactive properties, mainly via ETB receptors.

    CAS  PubMed  Google Scholar 

  24. Alberts GF, Peifley KA, Johns A, et al.: Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994, 269:10112–10118.

    CAS  PubMed  Google Scholar 

  25. Fujisaki H, Ito H, Hirata Y, et al.: Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995, 96:1059–1065. Important study demonstrating that ET-1 expression is regulated in an autocrine fashion through ETA-receptors in cardiac fibroblasts.

    CAS  PubMed  Google Scholar 

  26. Barton M, Shaw S, d’Uscio LV, et al.: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA-receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238:861–865.

    Article  CAS  PubMed  Google Scholar 

  27. Ito H, Hirata Y, Adachi S, et al.: Endothelin-1 is an autocrine/ paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993, 92:398–403.

    Article  CAS  PubMed  Google Scholar 

  28. Iwasaki S, Homma T, Matsuda Y, Kon V: Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem 1995, 270:6997–7003.

    Article  CAS  PubMed  Google Scholar 

  29. Malek A, Izumo S: Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am J Physiol 1992, 263:C389-C396.

    CAS  PubMed  Google Scholar 

  30. Wesson De, Simoni J, Greeen DF: Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular endothelial cells. J Clin Invest 1998, 101:578–583.

    CAS  PubMed  Google Scholar 

  31. Matsuura A, Yamochi W, Hirata K, et al.: Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998, 32:89–95. This study demonstrated autocrine regulation between VEGF and ET-1.

    CAS  PubMed  Google Scholar 

  32. Corder R, Carrier M, Khan N, et al.: Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Cardiovasc Pharmacol 1995, 26:(suppl 3):56–58.

    Google Scholar 

  33. Schwarting A, Schlaak J, Lotz J, et al.: Endothelin-1 modulates the expression of adhesion molecules on fibroblast-like synovial cells (FLS). Scand J Rheumatol 1996, 25:246–256.

    CAS  PubMed  Google Scholar 

  34. Boulanger C, Lüscher TF: Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990, 85:587–590.

    CAS  PubMed  Google Scholar 

  35. Stewart D, Cernacek P, Mohamed F, et al.: Role of cyclic nucleotides in the regulation of endothelin-1 production by human endothelial cells. Am J Physiol 1994, 266:H944-H951.

    CAS  PubMed  Google Scholar 

  36. Wada A, Tsutamato T, Maeda Y, et al.: Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol 1996, 270(part 2):1819–824.

    Google Scholar 

  37. Morey AK, Razandi M, Pedram A, et al.: Oestrogen and progesterone inhibit the stimulated production of endothlin-1. Biochem J 1998, 330:1097–1105.

    CAS  PubMed  Google Scholar 

  38. Wypij DM, Nichols JS, Novak PJ, et al.: Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 1992, 43:845–853.

    Article  CAS  PubMed  Google Scholar 

  39. Guo C, Rabinovitch M: A novel chymase cDNA cloned from rat pulmonary artery smooth muscle cells with increased vascular expresion in spontaneously hypertensive rats [abstract]. Circulation 1998, 98:745.

    Google Scholar 

  40. Ikeda K, Emoto N, Matsuura A, et al.: Molecular cloning and characterization of a novel metalloprotease that cleaves big-endothelin-1 to produce active endothelin-1 [abstract]. Circulation 1998, 98:745.

    Google Scholar 

  41. Hoang MV, Turner AJ: Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J 1998, 327:23–26. An interesting study demonstrating that ECE-1 is not specific for big-ET-1 conversion, but also for the hydrolysis of bradykinin, an action shared by angiotensin converting enzymes.

    Google Scholar 

  42. Johnson GD, Stevenson T, Ahn K: Hydrolysis of peptide hormones by endothelin-converting enzyme-1: a comparison with neprilysin. J Biol Chem 1999, 274:4053–4058.

    Article  CAS  PubMed  Google Scholar 

  43. Hasegawa H, Hiki K, Sawamura T, et al.: Purification of a novel endothelin-converting enzyme specific for big endothelin-3. FEBS Lett 1998, 428:394–398.

    Article  Google Scholar 

  44. Hofman FM, Chen P, Jeyaseelan R, et al.: Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells. Blood 1998, 92:3064–3072.

    CAS  PubMed  Google Scholar 

  45. Peifley KA, Winkles JA: Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem Biophys Res Com 1998, 242:202–208.

    Article  CAS  PubMed  Google Scholar 

  46. Hafizi S, Wharton J, Chester AH, et al.: Endothelin-1 stimulates collagen synthesis in cultured human cardiac fribroblasts via the ETA receptor [abstract]. Circulation 1998, 98:79.

    Google Scholar 

  47. Marini M, Carpi S, Bellini A, et al.: Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem Biophys Res Commun 1996, 220:896–899.

    Article  CAS  PubMed  Google Scholar 

  48. Weissber PL, Witchel C, Davenport AP, et al.: The endothelin peptides ET-1, ET-2, ET-3 and sarafatoxin S6c are comitogenic with platelet derived growth factor for vascular smooth muscle cells. Atherosclerosis 1990, 83:257–262.

    Article  Google Scholar 

  49. Pedram A, Razandi M, Hu RM, Levin ER: Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J Biol Chem 1998, 273:13966–13972.

    Article  CAS  PubMed  Google Scholar 

  50. Suzuki E, Nagata D, Kakoki M, et al.: Molecular mechanisms of endothelin-1-induced cell-cycle progression. Involvement of extracellular signal-regulated kinase, protein kinase C, and phosphatidylinositol e-kinase at distinct points. Circ Res 1999, 84:611–619.

    CAS  PubMed  Google Scholar 

  51. Schlüter KD, Katzer C: PTHrP(1-16) binds and activates cardiac ETA receptors. Circulation 1999, 100 (suppl):I-192.

    Google Scholar 

  52. Barton M, Vos I, Shaw S, et al.: Dysfunctional nitric oxide synthase as a determinant of salt-sensitive hypertension. Mechanisms of renal artery dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 2000, in press.

  53. Barton M, Carmona R, Morawietz H, et al.: Obesity is associated with tissue-specific activation of tissue angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 2000, in press.

  54. Lerman A, Edwards BS, Hallett JW, et al.: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991, 325:997–1001. First study to suggest involvement of ET-1 in human atherosclerosis.

    CAS  PubMed  Google Scholar 

  55. Stewart DJ, Kubac G, Costello KB, Cernacek P: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991, 18:38–43.

    CAS  PubMed  Google Scholar 

  56. Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 1989, 161:562–567.

    Article  CAS  PubMed  Google Scholar 

  57. Margulies KB, Hildebrand FJ, Lerman A, et al.: Increased endothelin in experimental heart failure. Circulation 2000, in press.

  58. Lüscher TF, Barton M: Endothelin and endothelin antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, in press.

  59. Zeiher AM, Ihling C, Pistorius K, et al.: Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994 344:1405–1406.

    Article  CAS  PubMed  Google Scholar 

  60. Lerman A, Holmes DJ, Bell MR, et al.: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995, 92:2426–2431.

    CAS  PubMed  Google Scholar 

  61. Breslow JL: Mouse models of atherosclerosis. Science 1996, 272:685–688.

    Article  CAS  PubMed  Google Scholar 

  62. Plump AS, Smith JD, Hayek T, et al.: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficent mic created by homologous recombination in ES cells. Cell 1992, 71:343–353.

    Article  CAS  PubMed  Google Scholar 

  63. Zhang S, Reddick TL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468–471.

    Article  CAS  PubMed  Google Scholar 

  64. Powell-Braxton L, Veniant M, Latval RD, et al.: A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998, 4:934–938 (published erratum appears in Nat Med 1998, 4(10):1200).

    Article  CAS  PubMed  Google Scholar 

  65. Breslow JL: Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc Natl Acad Sci U S A 1993, 90:8314–8318.

    Article  CAS  PubMed  Google Scholar 

  66. Davignon J, Cohn JS, Mabile L, Bernier L: Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999, 286:115–143.

    Article  CAS  PubMed  Google Scholar 

  67. Barton M, Haudenschild CC, d’Uscio LV, et al.: Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apoE-deficient mice. Proc Natl Acad Sci U S A 1998, 95:14367–14372.

    Article  CAS  PubMed  Google Scholar 

  68. Ludmer PL, Selwyn AP, Shook TL, et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046–1051. This important study first demonstrated impairment of endotheliumdependent vasomotion in patients with coronary atherosclerosis.

    CAS  PubMed  Google Scholar 

  69. Best PJ, Lerman LO, Romero JC, et al.: Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia In vitro. Arterioscler Thromb Vasc Biol 1999, 19:2769–2775.

    CAS  PubMed  Google Scholar 

  70. Best PJ, McKenna CJ, Hasdai D, et al.: Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 1999, 99:1747–1752.

    CAS  PubMed  Google Scholar 

  71. Barton M, D’Uscio L, Shaw S, et al.: ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 499–504.

  72. Bauersachs J, Fraccarollo D, Widder J, Ertl G: Endothelial dysfunction in rats with chronic myocardial infarction by treatment with endothelin antagonists [abstract]. J Am Coll Cardiol 1999, 33(suppl A):178.

    Google Scholar 

  73. Anderson TJ, Meredith IT, Yeung AC, et al.: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488–493.

    Article  CAS  PubMed  Google Scholar 

  74. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995, 346:467–471.

    Article  CAS  PubMed  Google Scholar 

  75. Kowala MC, Rose PM, Stein PD, et al.: Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995, 146:819–826. This study suggested involvement of ET-1 in monocyte adhesion and formation of fatty streaks in hamsters with hypercholesterolemia.

    CAS  PubMed  Google Scholar 

  76. Picard P, Donnelly T, Babaei S, et al.: Inhibiton of atherosclerosis in LDL receptor deficient mice by endothelin receptor blockade [abstract]. Circulation 1998, 98:310.

    Google Scholar 

  77. Iwasa S, Fan J, Miyauchi T, Watanabe T: Non-selective endothelin receptor antagonist, SB209670, reduces diet-induced hypercholesterolemia and atherosclerosis in apolipoproteinE-deficient mice [abstract]. Circulation 1999, 100 (suppl):474.

    Google Scholar 

  78. Wang X, Douglas SA, Louden C, et al.: Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 1996, 78:322–328.

    CAS  PubMed  Google Scholar 

  79. Douglas SA, Ohlstein EH: Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. J Cardiovasc Pharmacol 1993, 22:S371-S373.

    Article  CAS  PubMed  Google Scholar 

  80. Douglas SA, Vickery-Clark LM, Louden C, Ohlstein EH: Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat. Cardiovasc Res 1995, 29:641–646.

    Article  CAS  PubMed  Google Scholar 

  81. Tsujino M, Hirata Y, Eguchi S, et al.: Nonselective ETA/ETB receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. Life Sci 1995, 56:L449–454.

    Article  Google Scholar 

  82. Münter K, Hergenröder S, Unger L, Kirchengast M: Oral treatment with and ETA-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett 1996, 6:90–92.

    Google Scholar 

  83. McKenna CJ, Burke SE, Opgenorth TJ, et al.: Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation 1998, 97:2551–2556.

    CAS  PubMed  Google Scholar 

  84. Kirchengast M, Münter K: Endothelin and restenosis. Cardiovasc Res 1998, 39:550–555.

    Article  CAS  PubMed  Google Scholar 

  85. Watschinger B, Vychytil A, Attar M, et al.: Pattern of endothelin immunostaining during rejection episodes after kidney transplantation. Clin Nephrol 1994, 41:86–93.

    CAS  PubMed  Google Scholar 

  86. Giaid A, Saleh D, Yanagisawa M, Forbes RD: Endothelin-1 immunoreactivity and mRNA in the transplanted human heart. Transplantation 1995, 59:1308–1313.

    CAS  PubMed  Google Scholar 

  87. Ravalli S, Szaboles M, Albala A, et al.: Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation 1996, 94:2096–2102.

    CAS  PubMed  Google Scholar 

  88. Shennib H, Serrick C, Saleh D, et al.: Alterations in bronchoalveolar lavage and plasma endothelin-1 levels early after lung transplantation. Transplantation 1995, 59:994–998.

    Article  CAS  PubMed  Google Scholar 

  89. Geny B, Piquard F, Lonsdorfer J, Haberey P: Endothelin and heart transplantation. Cardiovasc Res 1998, 39:556–562.

    Article  CAS  PubMed  Google Scholar 

  90. Levine SM, Bryan CL: Bronchiolitis obliterans in lung transplant recipients: the "thorn in the side" of lung transplantation [editorial]. Chest 1995, 107:894–897.

    CAS  PubMed  Google Scholar 

  91. Takeda S, Sawa Y, Minami M, et al.: Experimental bronchiolitis obliterans induced by in vivo HJV-liposome-mediated endothelin-1 gene transfer Ann Thorac Surg 1997, 63:1562–1567.

    Article  CAS  PubMed  Google Scholar 

  92. Orth SR, Odoni G, Amann K, et al.: The ETA receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J Am Soc Nephrol 1999, 10:387–391. Important study indicating that ETA receptor blockade may have inhibitory effects on transplant-associated arteriosclerosis independent from immunosuppression.

    CAS  PubMed  Google Scholar 

  93. Braun C, Conzelmann T, Vetter S, et al.: Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation 1999, 68:739–746.

    Article  CAS  PubMed  Google Scholar 

  94. Isobe M, Suzuki J, Morishita R, et al.: Downregulation of endothelin expression in allograft coronary arteries after gene therapy targeting Cdk2 kinase Transplant Proc 1998, 30:1007–1008.

    Article  CAS  PubMed  Google Scholar 

  95. Shennib H, Lee AG, Kuang JQ, et al.: Efficacy of administering an endothelin-receptor antagonist (SB209670) in ameliorating ischemia-reperfusion injury in lung allografts. Am J Respir Crit Care Med 1998, 157:1975–1981.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology, Department of Medicine, University Hospital Zürich, Rämistrasse 100, CH-8091, Zürich, Switzerland

    Matthias Barton MD

Authors
  1. Matthias Barton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barton, M. Endothelial dysfunction and atherosclerosis: Endothelin receptor antagonists as novel therapeutics. Current Science Inc 2, 84–91 (2000). https://doi.org/10.1007/s11906-000-0064-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-000-0064-5

Keywords

Search

Navigation